Blue Shield of California aims to produce 5 to 10 low-cost generic drugs in its initial effort, and the BCBSA/Civica group hopes that the first will be available by early 2022. (Photo: Shutterstock)
It may sound counter-intuitive, but a group of insurers is partnering with the "public asset" Civica Rx to bring down the cost of prescription drugs by producing generic versions at lower prices.
The New York Times reports that the insurers—the Blue Cross Blue Shield Association and 18 of its member organizations—have pledged $55 million in a partnership agreement with nonprofit Civica Rx "to create cheaper versions of expensive generic drugs for which there is little competition."
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Marlene Satter
Marlene Y. Satter has worked in and written about the financial industry for decades.
